Stefan Schreiber, DDW 2021: Phase 2b/3 SELECTION and Long Term Extension Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the Phase 2b/3 SELECTION and Phase 3 SELECTION long term extension study, investigating filgotinib for the treatment of ulcerative colitis.
The abstract entitled ‘133: SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTIONLTE LONG-TERM EXTENSION STUDY’ was presented at DDW 2021, May 21-23.
- What is the rationale for the use of filgotinib in ulcerative colitis? (0:11)
- What did the SELECTION induction trials teach us about the efficacy and safety of filgotinib in patients with moderate to severely active ulcerative colitis? (1:25)
- Could you give us a brief overview of the aims and design of the maintenance study? (2:30)
- What were the results and conclusions of the study? (3:18)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, and Falk, outside the submitted DDW work.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Digestive Disorders
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Guselkumab: an investigational monoclonal antibody for ulcerative colitis: Jessica Allegretti, DDW 2023
Guselkumab is a fully human monoclonal antibody IL-23 p19 subunit antagonist currently being investigated in hard to treat, moderately to severely active ulcerative colitis. We were delighted to speak with Dr Jessica Allegretti, (Brigham and Women’s Hospital, Boston, MA, USA) around the burden of ulcerative colitis in patients with inadequate response to currently approved treatments, […]
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!